Physician profile
Ali Junaid Husain
NPI 1316998883
$8,604.92
in general payments reported to CMS, 2019-2025
35 companies · $1,438 in 2025
The $1,438 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $92.18 · 2021: $1,123 · 2022: $1,617 · 2023: $1,746 · 2024: $1,903 · 2025: $1,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,983 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,983.26 |
| Education | $103.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,225.35 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,266.99 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $924.26 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $684.12 | 2019-2025 | |
| Celgene Corporation | $566.09 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $407.87 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $332.15 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $217.48 | 2021-2023 | |
| Genzyme Corporation | $215.82 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $201.28 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $180.15 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $174.79 | 2023-2025 | Omvoh, Zepbound |
| Daiichi Sankyo INC. | $165.74 | 2019-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $159.12 | 2019-2024 | Dificid, Zinplava |
| Ironwood Pharmaceuticals, INC | $158.98 | 2019-2024 | Linzess |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $148.75 | 2024-2025 | Iqirvo, Bylvay |
| Angiodynamics, INC. | $95.23 | 2024 | Nanoknife |
| Madrigal Pharmaceuticals | $66.31 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $44.22 | 2023 | Rebyota |
| Shire North American Group INC | $40.68 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.61 | 2019-2021 | |
| Amgen INC. | $32.30 | 2023 | Amjevita, Avsola |
| Braintree Laboratories, INC. | $30.69 | 2021-2023 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $27.07 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $22.11 | 2021 | |
| Mauna Kea Technologies, INC. | $21.53 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.40 | 2023 | Cyltezo |
| Aimmune Therapeutics, INC. | $20.35 | 2025 | Zenpep |
| Ardelyx, INC. | $20.33 | 2023 | Ibsrela |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Organon LLC | $18.34 | 2023 | |
| Ucb, INC. | $17.72 | 2019 | |
| Fresenius Kabi USA, LLC | $17.69 | 2023 | Idacio |
| Medtronic, INC. | $13.98 | 2022 | |
| Allergan, INC. | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Husain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.